PRISM MarketView – Biotech Breakfast
- Mobile-Health Network Solutions (MNDR) IPOs; Q32 Bio Surges; EMA Concludes GLP-1 Drugs Not Associated with Suicidal Thoughts New York, N.Y., April 15, 2024 – PRISM MarketView – Healthcare equities finished lower on Friday, in line with broad declines across the market.
- 04/15/2024
|
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia
- Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced details regarding the planned design of its upcoming TRANQUILITY In-Care Phase 3 trial to evaluate BXCL501, the company's investigational proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with Alzheimer's dementia (AAD) in the care setting.
- 04/10/2024
|
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
- NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 3,054,609 shares of Common Stock at a combined offering price of $2.901 per Share and Accompanying Warrant and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 5,565,027 shares of Common Stock and Accompanying Warrants to purchase up to 5,565,027 shares of Common Stock at a combined offering price of $2.900 per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per Share and Accompanying Warrant less the $0.001 exercise price per share of the Pre-Funded Warrants, for aggregate gross proceeds to the Company of approximately $25 million (excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants and the Accompanying Warrants). The Pre-Funded Warrants have an exercise price of $0.001 per share of Common Stock and are exercisable at any time after the date of issuance, subject to certain ownership limitations. The Accompanying Warrants have an exercise price of $3.20 per share of Common Stock, are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire five years from the date of issuance.
- 03/25/2024
|
BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
- Newly granted patent aligns with Company's focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501 Newly granted patent aligns with Company's focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501
- 03/15/2024
|
BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript
- BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q4 2023 Earnings Conference Call March 12, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Vince O'Neill - Chief of Product and Development Medical Officer Richard Steinhart - Chief Financial Officer Robert Risinger - Chief Medical Officer, Neuroscience Matt Wiley - Chief Commercial Officer Conference Call Participants Greg Harrison - Bank of America Robyn Karnauskas - Truist Securities Graig Suvannavejh - Mizuho Securities Sumant Kulkarni - Canaccord Genuity Ram Selvaraju - H.C. Wainwright Colin Bristow - UBS Samir Devani - Rx Securities Operator Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will include an update on the company's late stage clinical programs and the discussion of financial results for the fourth quarter and full-year 2023.
- 03/12/2024
|
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
- Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug Administration for TRANQUILITY and SERENITY programs C onference call and webcast set for 8:00 a.m. ET today NEW HAVEN, Conn.
- 03/12/2024
|
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
- There's a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they're intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy.
- 03/07/2024
|
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
- NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2023 financial results on Tues., March 12, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company's financial results and provide a general business update.
- 03/01/2024
|
BioXcel Therapeutics Announces Termination of Proposed Public Offering
- NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, previously announced on February 8, 2024. As a result of such termination, no securities of the Company are being sold pursuant to the offering.
- 02/13/2024
|
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
- Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability
- 02/12/2024
|
Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?
- BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Friday after the commercial-stage biopharmaceutical company announced a proposed underwritten public offering for its shares. This public offering includes $60 million shares of BTAI stock.
- 02/09/2024
|
BioXcel Therapeutics Announces Proposed Public Offering
- NEW HAVEN, Conn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to $9.0 million of additional shares of common stock at the public offering price, less the underwriting discounts and commissions.
- 02/08/2024
|
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
- Human proof of concept portion of the trial expected to begin in H1 2024; led by Georgetown Lombardi Comprehensive Cancer Center
- 02/06/2024
|
BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine
- Aligns with Company's strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer's patients
- 02/05/2024
|
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
- Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer's disease and BXCL502 as a potential treatment for chronic use Dr. Sandra Comer to discuss BXCL501 as a potential treatment for opioid withdrawal NEW HAVEN, Conn., Dec. 12, 2023 (GLOBE NEWSWIRE) -- As previously announced, BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, will host a virtual Neuroscience R&D Day focused on BXCL502 and other neuroscience pipeline candidates.
- 12/12/2023
|
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
- Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer Rajiv Patni, M.D.
- 12/11/2023
|
7 Penny Stocks With Low Floats and High Short Interest
- There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.
- 11/24/2023
|
BioXcel Therapeutics stock plummets as 3Q earnings fall short of expectations
- BioXcel Therapeutics Inc (NASDAQ:BTAI) shares fell almost 35% after it reported a revenue miss and greater than forecast loss for the third quarter. The New Haven, Connecticut-based biopharmaceutical company reported sales of $341,000, up from $137,000 in the year-ago quarter but below estimates of $840,000.
- 11/14/2023
|
5 Most Active Penny Stocks Today & Why They're Moving Now
- Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
- 11/01/2023
|
Penny Stocks To Buy Today? 4 To Watch Now
- Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market.
- 10/31/2023
|
4 Penny Stocks To Watch Today With Big News, Time To Buy?
- Trading penny stocks can be a risky endeavor, but having access to quality news and information can help mitigate some of that risk. As an investor or trader, it's critical to understand how news events can impact penny stocks and how to use news to your advantage when developing your trading strategy.
- 10/30/2023
|
3 Penny Stocks To Buy For Under $5, Are They Worth It?
- Penny stocks are defined as stocks trading for under $5. They typically include start-up or emerging-growth stage companies starting from the grassroots.
- 10/26/2023
|
5 Hot Penny Stocks To Watch In The Stock Market Today
- Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, understanding things like stock market news and events is important.
- 10/25/2023
|
Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today?
- BioXcel Therapeutics (NASDAQ: BTAI ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its Tranquility II clinical trial. According to a press release from the company, a third-party audit of its Phase 3 study returned positive results.
- 10/25/2023
|
BioXcel Therapeutics shares pop after audit of Alzheimer's trial data
- Shares of BioXcel Therapeutics Inc. BTAI, +0.86% jumped more than 40% premarket on Wednesday after the company said an independent audit of Alzheimer's trial data found no issues impacting the data's integrity and reliability.
- 10/25/2023
|
Why Shares of BioXcel Therapeutics Fell This Week
- The company has one marketed treatment -- Igalmi, which reduces agitation in patients with bipolar disorder or schizophrenia. The most advanced candidate in BioXcel's pipeline is BXCL501, which aims to reduce agitation in dementia patients.
- 09/28/2023
|
Why BioXcel Therapeutics Stock Flopped Again Today
- The biotech takes another hit following its earnings release on Monday. Several analysts became notably more bullish on its prospects.
- 08/15/2023
|
3 Biotech Stocks to Sell in August Before They Crash and Burn
- Investors who've dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure is incredibly common for firms that engage in the development of pharmaceuticals.
- 08/14/2023
|
Why BioXcel Therapeutics Stock Is Getting Crushed Today
- BioXcel announced Q2 results and a major strategic shift this morning. The biotech specialist has halted plans for Phase 2 clinical trials that were important to the bull thesis on its stock.
- 08/14/2023
|
Why Is BioXcel Therapeutics (BTAI) Stock Down 46% Today?
- BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Monday after the biopharmaceutical company announced layoffs. This has BioXcel Therapeutics cutting over 50% of its workforce.
- 08/14/2023
|
Biotech Stock Plummets After Halving Workforce
- BioXcel Therapeutics Inc (NASDAQ:BTAI) is plummeting, last seen down 46.3% to trade at $3.98 after its second-quarter earnings report.
- 08/14/2023
|
BioXcel Therapeutics stock plummets as it cuts jobs in half to focus on AI-powered innovation
- BioXcel Therapeutics Inc (NASDAQ:BTAI) stock opened close to 45% lower as trading kicked off in New York on Monday after it revealed it would be wielding the axe across its business. Around half of BioXcel's workforce is to be laid off whilst it cuts operations and focusses down solely on its most advance treatment line only.
- 08/14/2023
|
BioXcel Therapeutics to cut workforce 58%, stock falls 27%
- Shares of BioXcel Therapeutics BTAI, +0.14% tumbled 27% premarket on Monday as the biopharma company said it would cut its workforce by about 58%. BioXcel, which uses artificial intelligence to develop medicines, also said it is looking to reduce more than 50% of its cash burn, to about $80 million annually going forward.
- 08/14/2023
|
BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023
- NEW HAVEN, Conn., July 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter 2023 financial results on Monday, August 14, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company's financial results and to provide a general business update.
- 07/31/2023
|
3 Biotech Stocks to Sell Before They Damage Your Portfolio
- There are several reasons that investors should be cautious about buying or holding biotech stocks at this point. First, the Street is generally bearish on the sector lately.
- 07/12/2023
|
Why BioXcel Therapeutics Stock Was Bouncing Back This Week
- The biotech was in the running for Comeback Stock of the Week. It had tanked significantly after publishing the results of a clinical trial.
- 07/07/2023
|
BioXcel: Data Integrity Concerns Muddy Regulatory Outlook (Rating Downgrade)
- BioXcel Therapeutics faces regulatory challenges after the FDA found inconsistencies in one of its clinical trial sites, jeopardizing the supplementary approval of its drug, IGALMI. BioXcel's initiated an internal investigation and independent audit in response, but doubts persist about their commitment to regulatory compliance and ethical conduct, potentially impacting their industry reputation. Given the regulatory uncertainties and the company's existing marketing issues, I have revised my investment recommendation to a "Strong Sell" for BioXcel.
- 06/30/2023
|
Why Shares of BioXcel Therapeutics Are Plunging Thursday
- The company said phase 3 trial results for BXCL501 were generally positive. BioXcel said there was a question regarding one of the trial site's investigators.
- 06/29/2023
|
Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?
- BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Thursday after the company released its latest clinical trial data. BioXcel Therapeutics notes that its Phase 3 clinical trial of BXCL501, a treatment of Alzheimer's disease-related agitation, met its primary and secondary endpoints.
- 06/29/2023
|
BioXcel Therapeutics's drug meets key trial goal to treat Alzheimer's patients
- BioXcel Therapeutics said on Thursday its experimental drug to treat agitation related to Alzheimer's disease met the main goal in a late-stage study, but the results were marred by concerns over data integrity at one of the trial sites.
- 06/29/2023
|
3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally
- At the heart of every idea for short-squeeze stocks to buy is the ability to make a massive amount of money in a short time period. For a quick recap, those attempting to spark a gamma squeeze essentially take the opposite side of the bearish bet.
- 06/15/2023
|
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
- NEW HAVEN, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in fireside chats at two upcoming investor conferences. He will be joined by Robert Risinger, M.D., Chief Medical Officer, Neuroscience, and Matt Wiley, Chief Commercial Officer.
- 06/01/2023
|
BioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 Will
- BioXcel has just published the results of the first part of the Serenity III trial in which, although clinically good results, it has not been able to achieve statistically significant. This first part of the trial has served the company to choose a more optimal dose for the second part. The next results of Tranquility II in June constitute one of the main catalysts that BioXcel presents this year 2023.
- 05/28/2023
|
Why Shares of BioXcel Therapeutics Are Dropping Thursday
- BioXcel Therapeutics got approval last year for Igalmi to treat acute agitation in adults with schizophrenia or bipolar disorder. The drug is in a trial to treat patients in an at-home setting.
- 05/25/2023
|
BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain
- Shares of BTAI stock plummeted after BioXcel's Igalmi missed the mark in patients with agitation due to schizophrenia or bipolar disorders. The post BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain appeared first on Investor's Business Daily.
- 05/25/2023
|
Why These 3 Nasdaq Stocks Were Glowing Green This Week
- A fair number of Nasdaq-listed growth stocks moved higher this week. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week.
- 05/11/2023
|
Why BioXcel Therapeutics Stock Marched Higher Today
- BioXcel Therapeutics announced 2023 first-quarter earnings today. While revenue for the three-month period wasn't a needle-mover, investors appear to be intrigued by a series of upcoming trial readouts.
- 05/08/2023
|
BioXcel Therapeutics, Inc. (BTAI) Q1 2023 Earnings Call Transcript
- BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Rob Risinger - Chief Medical Officer, Neuroscience Matt Wiley - Chief Commercial Officer Richard Steinhart - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Mary Kate - Bank of America Colin Bristow - UBS Yatin Suneja - Guggenheim Partners Sumant Kulkarni - Canaccord Genuity Ram Selvaraju - H.C. Wainwright Operator Good morning, and welcome to the BioXcel Therapeutics First Quarter 2023 Financial Results Conference Call.
- 05/08/2023
|
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
- NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Tuesday, May 9, 2023 at 10:15 a.m. PT. He will be joined by Robert Risinger, M.D., Chief Medical Officer, Neuroscience, and Matt Wiley, Chief Commercial Officer.
- 05/02/2023
|
BioXcel Therapeutics: All Eyes On Igalmi's Ramp, Reiterating Hold Rating
- BioXcel Therapeutics: All Eyes On Igalmi's Ramp, Reiterating Hold Rating.
- 04/26/2023
|
BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023
- NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2023 financial results on Monday, May 8, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company's financial results and to provide a general business update.
- 04/24/2023
|
BioXcel Therapeutics' Igalmi Commercial Launch: Not As Bad As Some May Think
- BioXcel Therapeutics, Inc. has just released results for the fourth quarter of 2022. Some analysts have expressed doubts about the commercial success of its Igalmi launch.
- 03/16/2023
|
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
- NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company's financial results and to provide a general business update.
- 02/23/2023
|
BioXcel BXCL701: Another Step Forward In The Race For An mCRPC Treatment
- BioXcel has just published top-line data from the Phase IIa trial of BXCL701 for mSCNC with very promising results. These results position BXCL701 as a valuable asset for the first time.
- 02/17/2023
|
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
- NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present corporate updates and anticipated milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 9:45 a.m. PST.
- 12/22/2022
|
Why BioXCel Therapeutics Stock Jumped This Week
- A couple of analysts recently upgraded their views on the biotech stock.
- 12/15/2022
|
2 Beaten-Down Stocks to Watch Closely Next Year
- These biotechs could skyrocket in 2023, but only if they can execute their plans.
- 12/06/2022
|
Why BioXcel Therapeutics Stock Triumphed This Week
- An analyst feels that the best is shortly to come for the company.
- 12/02/2022
|
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
- NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a virtual fireside chat at the Bank of America 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 1:45 p.m. Eastern Time. Management will discuss the Company's neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. They will also discuss the Company's ongoing commercial launch strategy for IGALMI™ (dexmedetomidine) sublingual film.
- 12/01/2022
|
Is This Soaring Growth Stock a Buy?
- The answer may depend on your risk tolerance.
- 11/20/2022
|
Seeking Treatment For Agitation In Alzheimer's Patients: A Race For A Multi-Billion Opportunity, And BioXcel's BXCL501 Has The Edge
- Currently, several pharmaceutical companies are testing candidates' drugs and some of them are in the final stages of trials. The huge revenue potential is at stake in this race for the best anti-agitation drug for dementia and Alzheimer's patients.
- 11/14/2022
|
BioXcel Therapeutics to Present at Two Upcoming Investor Conferences
- NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in fireside chats at two upcoming investor conferences. Management will discuss the Company's neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. They will also discuss the Company's ongoing commercial launch strategy for IGALMI™ (dexmedetomidine) sublingual film.
- 11/14/2022
|
BioXcel Therapeutics, Inc. (BTAI) Q3 2022 Earnings Call Transcript
- BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Matt Wiley - Chief Commercial Officer Richard Steinhart - Chief Financial Officer Rob Risinger - Chief Medical Officer, Neuroscience Vincent O'Neill - Chief Medical Officer, Oncology Conference Call Participants Greg Harrison - Bank of America Colin Bristow - UBS Yatin Suneja - Guggenheim Partners Graig Suvannavejh - Mizuho Securities Ram Selvaraju - H.C. Wainwright Corinne Jenkins - Goldman Sachs Operator Good morning, and welcome to the BioXcel Therapeutics Third Quarter 2022 Financial Results Conference Call.
- 11/10/2022
|
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
- NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2022 financial results on Thursday, November 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company's financial results and to provide a general business update.
- 10/27/2022
|
BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
- NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 10:30 a.m. Eastern Time. Management will discuss the Company's neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. They will also discuss the Company's commercial launch strategy for IGALMI™ (dexmedetomidine) sublingual film.
- 09/07/2022
|
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q2 2022 Results - Earnings Call Transcript
- BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Richard Steinhart - Senior Vice President and Chief Financial Officer Matt Wiley - Chief Commercial Officer Robert Risinger - Chief Medical Officer, Neuroscience Frank Yocca - Chief Scientific Officer Vincent O'Neill - Senior Vice President & Chief Medical Officer, Oncology Conference Call Participants Greg Harrison - Bank of America Robyn Karnauskas - Truist Securities Sumant Kulkarni - Canaccord Colin Bristow - UBS Richard Allen - Mizuho Securities Ram Selvaraju - H.C. Wainwright Corinne Jenkins - Goldman Sachs Operator Good morning and welcome to the BioXcel Therapeutics Second Quarter 2022 Financial Results Conference Call.
- 08/09/2022
|
BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
- NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company's financial results and to provide a general business update.
- 07/26/2022
|
BioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great Asset
- BioXcel is currently conducting phase II and III trials of BXCL501 to treat acute agitation in patients with dementia and Alzheimer's. The results of phase II are expected very soon (July or August), and the results of phase III for the end of this year 2022.
- 07/19/2022
|
1 Beaten-Down Stock That Could Soar
- Will this biotech's recent rebound last?
- 07/16/2022
|
Why BioXcel Therapeutics Was a Winner This Week
- The stock is tagged as a buy by an investment bank initiating coverage.
- 07/08/2022
|
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
- NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences. Dr. Mehta will discuss the Company's neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. He will also discuss the Company's commercial and launch readiness plans for IGALMI™ (dexmedetomidine) sublingual film.
- 06/07/2022
|
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
- NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference now scheduled for Tuesday, May 24 at 9:00 a.m. ET. Dr. Mehta will discuss the Company's neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. He will also discuss the Company's commercial and launch readiness plans for IGALMI™ (dexmedetomidine) sublingual film.
- 05/20/2022
|
Why Shares of BioXcel Therapeutics Climbed 25.2% This Week
- With the company's launch of its first marketed drug on the horizon, investors showed some excitement.
- 05/19/2022
|
BioXcel Therapeutics (BTAI) CEO, Vimal Mehta on Q1 2022 Results - Earnings Call Transcript
- BioXcel Therapeutics Inc. (NASDAQ:BTAI ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer Matt Wiley - Chief Commercial Officer Richard Steinhart - Vice President, Chief Financial Officer Rob Risinger - Chief Medical Officer, Neuroscience Conference Call Participants Greg Harrison - Bank of America Robyn Karnauskas - Truist Securities Sumant Kulkarni - Canaccord Yatin Suneja - Guggenheim Partners Colin Bristow - UBS Corinne Jenkins - Goldman Sachs Anita Dushyanth - Berenberg Operator Good morning and welcome to the BioXcel Therapeutics first quarter 2022 financial results conference call. At this time, all participants are in a listen-only mode.
- 05/09/2022
|
Why BioXcel Therapeutics Shares Went Up 12.9% This Week
- The company is stepping up its efforts to expand the label uses of its lead therapy.
- 05/05/2022
|
2 Small-Cap Stocks With Monster Upsides, According to Wall Street
- Sometimes analysts are on the spot, and other times, not so much.
- 04/30/2022
|
BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022
- NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2022 financial results on Monday, May 9, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company's financial results and to provide a general business update.
- 04/26/2022
|
BioXcel Therapeutics: At A Turning Point After The Approval Of BXCL501
- On April 6, BioXcel announced the FDA's approval of BXCL501 to treat acute agitation in patients with schizophrenia and bipolar syndrome.
- 04/08/2022
|
Best Stocks To Buy Now? 3 Health Care Stocks For Your List
- Could health care stocks be the play amidst the current volatility in markets?
- 04/08/2022
|
Why BioXcel Therapeutics Stock Is Surging Today
- BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in.
- 04/06/2022
|
BioXcel says the FDA approved its therapy for adults with schizophrenia or bipolar disorder
- Shares of BioXcel Therapeutics Inc. BTAI, -2.98% jumped 14.6% in premarket trading on Wednesday after the company said the Food and Drug Administration approved Igalmi, a sublingual film used to treat agitation associated with schizophrenia or bipolar disorder in adults. The therapy is expected to launch in the U.S. in the second quarter of this year.
- 04/06/2022
|
Why Shares of BioXcel Therapeutics Shot Up 25.4% This Week
- Investors may be anticipating a positive review by the FDA of the company's lead drug candidate.
- 03/24/2022
|
BioXcel Therapeutics Inc.: Speculative Buy To Play The PDUFA For BXCL501 In April
- We are initiating coverage on BTAI with a target price of USD 126 (+600% potential upside) and a potential 60% downside (~$7 cash value). We like the risk-reward set-up for the company.
- 03/21/2022
|
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2021 Results - Earnings Call Transcript
- BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2021 Results - Earnings Call Transcript
- 03/10/2022
|
BioXcel Therapeutics to Present at the Barclays Global Healthcare Conference
- NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will present at the upcoming Barclays Global Healthcare Conference on Tuesday, March 15 at 3:50 p.m. ET. Dr. Mehta will highlight the Company's neuroscience and immuno-oncology programs, artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process, and its commercial and launch readiness plans for its product candidate, BXCL501.
- 03/09/2022
|
Bioxcel Therapeutics: What To Expect From The Upcoming PDFA
- BioXcel Therapeutics faces its first PDUFA on April 5.
- 03/04/2022
|
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
- NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company's financial results and to provide a general business update.
- 02/24/2022
|
XBI: The Worst Is Over
- XBI: The Worst Is Over
- 01/27/2022
|
BioXcel Therapeutics: Facing An Important PDUFA Date In A Few Weeks
- BioXcel Therapeutics: Facing An Important PDUFA Date In A Few Weeks
- 01/26/2022
|
BioXcel Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
- NEW HAVEN, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present corporate updates and plans for 2022 at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, on Thursday, January 13, 2022 at 9:45 a.m. ET.
- 01/04/2022
|
BioXcel: Slump After PDUFA Extension Presents Buying Opportunity
- The FDA extended BTAI's PDUFA by three months, tanking the stock.
- 12/07/2021
|
Why BioXcel Therapeutics Stock Is Slumping Today
- A regulatory delay is weighing on the biotech today.
- 12/01/2021
|
BioXcel Therapeutics (BTAI) Stock: Why The Price Substantially Fell Today
- The stock price of BioXcel Therapeutics, Inc. (Nasdaq: BTAI) fell by over 18% pre-market today. This is why it happened.
- 12/01/2021
|
Why BioXcel Therapeutics Stock Is Crashing Today
- An analyst downgraded the stock.
- 11/15/2021
|
BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare Conference
- NEW HAVEN, Conn., Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Frank Yocca, Ph.D., Chief Scientific Officer , will participate in a fireside chat at the 12th Annual Jefferies Global Healthcare Conference in London on Wednesday, November 17, 2021 at 4:20 p.m. GMT / 11:20 a.m. ET. Dr. Mehta and Dr. Yocca will highlight the Company's neuroscience and immune-oncology programs, artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process, and its commercial and launch readiness plans for BXCL501.
- 11/11/2021
|
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2021 Results - Earnings Call Transcript
- BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
BioXcel Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
- NEW HAVEN, Conn., Oct. 27, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2021 financial results on Wednesday, November 10, 2021 before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company's financial results and to provide a general business update.
- 10/27/2021
|
BioXcel Therapeutics: Ready To Enter The Depression Therapeutic Field
- The company intends to expand the indication of BXCL501 to treat anxious depression.
- 10/24/2021
|
This High-Risk, High-Reward Stock Might Double Your Money
- After a difficult year, shares of this biotech could bounce back big.
- 10/20/2021
|
BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer
- Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell Neuroendocrine Prostate Cancer (SCNC)
- 10/18/2021
|
Why BioXcel Therapeutics Stock Is Sinking Today
- The company's chief commercial officer resigned.
- 10/14/2021
|
BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day
- Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders
- 09/23/2021
|
BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO
- BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma
- 09/15/2021
|
BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress
- NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that updates from its ongoing Phase 1b/2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the 2021 European Society for Medical Oncology (ESMO) Congress, which will take place virtually from September 16-21, 2021.
- 09/12/2021
|
BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021
- Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET – 2:00 PM ET
- 09/09/2021
|
BioXcel: Recent Selloff Offers A Very Good Opportunity To Entry At A Discount Price
- Any investor who looks at the stock price chart during this year 2021 will be shadowed by the sharp drop that it presents.
- 08/18/2021
|
BioXcel Therapeutics, Inc. (BTAI) CEO Dr. Vimal Mehta on Q2 2021 Results - Earnings Call Transcript
- BioXcel Therapeutics, Inc. (BTAI) CEO Dr. Vimal Mehta on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
- Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021
- 08/10/2021
|
This Under-the-Radar Dementia Treatment Could Reward Investors
- Want to dabble in the market for Alzheimer's therapies but avoid Biogen? Look no further.
- 07/29/2021
|
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
- NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will release its second quarter 2021 financial results on Tuesday, August 10, 2021 before the open of the U.S. financial markets. BioXcel's management team will also host a conference call and webcast at 8:30 AM EDT to discuss the Company's financial results and to provide a general business update.
- 07/28/2021
|
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
- NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 9:30 a.m. Eastern Time.
- 07/19/2021
|
Here's Why BioXcel Therapeutics Stock Got Hammered This Week
- Investors weren't happy about a secondary share offering.
- 06/25/2021
|
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
- NEW HAVEN, Conn., June 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 3,155,000 shares of common stock at a public offering price of $31.70 per share. In addition, a related party stockholder, BioXcel LLC, has granted the underwriters a 30-day option to purchase up to an additional 473,250 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds to the Company from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and offering expenses. The Company will not receive any of the proceeds from any sale of shares in this offering by BioXcel LLC.
- 06/23/2021
|
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
- NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, a related party stockholder, BioXcel LLC, expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional shares of common stock at the public offering price, less underwriting discounts and commissions.
- 06/22/2021
|
BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021
- Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET
- 06/18/2021
|
BioXcel: Upcoming PDUFA Makes Recent Drop Attractive
- BioXcel has a January 5 PDUFA for its lead candidate. The stock is down strongly.
- 05/29/2021
|
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
- FDA sets PDUFA action date for January 5, 2022
- 05/19/2021
|
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2021 Results - Earnings Call Transcript
- BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast
- NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Monday, May 10, 2021 at 8:30 AM Eastern Time to discuss its first quarter 2021 operating and financial results.
- 05/03/2021
|
BioXcel Therapeutics Announces Presentations on SERENITY I & II at the 2021 American Psychiatric Association Annual Meeting
- NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that data from its two pivotal Phase 3 trials (SERENITY I & II) of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II will be presented at the upcoming American Psychiatric Association (“APA”) Annual Meeting. The meeting will be held virtually on May 1-3, 2021.
- 04/26/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of BioXcel Therapeutics, Inc. (BTAI)
- New York, New York--(Newsfile Corp. - April 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/bioxcel-therapeutics-inc-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
- 04/16/2021
|
Why BioXcel Therapeutics Stock Is Plunging Today
- Investors were not impressed with the biotech's latest clinical update.
- 04/01/2021
|
FDA Gives Accelerated Review Tag To BioXcel's BXCL501 In Dementia-Related Agitation
- The FDA has designated Breakthrough Therapy status to BioXcel Therapeutics Inc's (NASDAQ: BTAI) BXCL501, to treat agitation associated with dementia. The designation intends to expedite the development and review of certain product candidates.
- 03/15/2021
|
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2020 Results - Earnings Call Transcript
- BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2020 Results - Earnings Call Transcript
- 03/11/2021
|
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
- 03/11/2021
|
Still Betting On BioXcel Therapeutics Stock
- We revisit BioXcel Therapeutics in-depth for the first time in five months. The company has seen several encouraging developments on the pipeline front and continues to receive favorable analyst commentary.
- 03/08/2021
|
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast
- NEW HAVEN, Conn., March 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, March 11, 2021 at 8:30 AM Eastern Time to discuss its fourth quarter and full year 2020 operating and financial results.
- 03/04/2021
|
BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation
- Review of TRANQUILITY data show ed 30 mcg dose met statistical significance across multiple scales
- 03/03/2021
|
BioXcel Therapeutics Appoints June Bray to Board of Directors
- Former Allergan executive brings extensive global regulatory experience across multiple therapeutic areas Former Allergan executive brings extensive global regulatory experience across multiple therapeutic areas
- 03/01/2021
|
BioXcel Therapeutics Starts Testing BXCL501 In Mid-Stage Delirium-Related Agitation Study
- BioXcel Therapeutics Inc (NASDAQ: BTAI) initiated the Phase 2 PLACIDITY trial evaluating BXCL501 to treat delirium-related agitation. The 20 subject-trial is designed to evaluate the safety, efficacy, and pharmacokinetics of BXCL501 in intensive care unit adult patients experiencing delirium-related agitation, including COVID-19 patients.
- 02/25/2021
|
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms
- Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET
- 02/12/2021
|
BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
- NEW HAVEN, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that an update from its ongoing Phase 1b/2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the virtual 2021 ASCO Genitourinary ("ASCO GU") Cancers Symposium. ASCO GU is being held from Thursday, February 11, 2021 to Saturday, February 13, 2021.
- 02/04/2021
|
Why BioXcel Therapeutics Stock Popped Today
- A Wall Street analyst has high hopes for the company.
- 02/01/2021
|
4 of the Best Investments to Start 2021
- High-growth names with positive catalysts that can outperform the markets make these some of the best investments to start 2021. The post 4 of the Best Investments to Start 2021 appeared first on InvestorPlace.
- 01/13/2021
|
BioXcel Therapeutics Has Compelling Upside Potential In Advance Of Multiple Data Readouts
- BioXcel uses a proprietary AI program to screen for ways to repurpose old drugs and screen for useful biomarkers that can allow for faster, safer, and cheaper drug development. BioXcel's lead asset BXCL501 is targeting a broad swath of agitation-related indications that could be very lucrative for the company.
- 12/27/2020
|
The Story of 2020 … and Possibly 2021 … and What it Means for Your Investments
- In the not-too-distant future, healthcare will look dramatically different from what we know today. From telemedicine to precision medicine to genetic therapy, the global healthcare industry is about to be shaken up like never before.
- 12/26/2020
|
BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
- Company to present corporate update and plans for 2021
- 12/17/2020
|
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD
- Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse
- 12/07/2020
|
BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
- NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference.
- 11/13/2020
|
BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
- Initiated rolling submission of New Drug Application (“NDA”) with U.S. Food and Drug Administration (“FDA”)
- 11/11/2020
|
BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting
- Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA®)
- 11/09/2020
|
BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast
- NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 AM Eastern Time to discuss its third quarter 2020 operating and financial results.
- 11/05/2020
|
Artificial Intelligence (AI) in Precision Medicine Market Growth, Share, Size, Trends, Top Companies and Forecast 2025
- Oct 07, 2020 (Market Insight Reports) --
Selbyville, Delaware Recently, Market Study Report, LLC, added a research on the ‘Artificial Intelligence (AI) in...
- 10/07/2020
|
BioXcel Therapeutics: Big Upside Potential (NASDAQ:BTAI)
- Today, we look at a promising CNS play called BioXcel Therapeutics. The shares have lost more than a third from their pre-secondary offering highs.
- 10/07/2020
|
Global Immuno-Oncology Market Size & Forecast 2020-2024 with Impact Analysis of COVID-19 & Profiles of Merck and Co., Pfizer, Amgen and Roche - ResearchAndMarkets.com
|
Global Biomarkers Market Forecasts for Immuno-Oncology Diagnostics 2020-2024 with Executive and Consultant Guides - ResearchAndMarkets.com
|
Two Sigma Advisers LP Takes Position in BioXcel Therapeutics Inc (NASDAQ:BTAI)
- Two Sigma Advisers LP bought a new stake in shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 27,200 shares of the company’s stock, valued at approximately $1,442,000. Two Sigma Advisers LP owned approximately 0.12% […]
- 10/03/2020
|
BioXcel Therapeutics: Opportunity Emerges During Pandemic While Mental Health Is Being Ignored (NASDAQ:BTAI)
- In 2020, the central nervous system (CNS) market has largely failed to keep up with $IBB. The current stock price of BioXcel Therapeutics is highly influenced by the approval and filing of the NDA for agitation in bipolar and schizophrenia.
- 09/23/2020
|
Evogene: Hidden Gems Of Computational Predictive Biology: (Part 4 Of 4), Canonic Ltd. (Medical Cannabis) (NASDAQ:EVGN)
- Despite its recent share price increase, Evogene continues to be undervalued given the sum of parts valuation of its 4 main subsidiaries and $45 million cash position.
- 09/23/2020
|
BTAI: TRANQUILITY Trial Readout Possible in 4Q20…
- By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update TRANQUILITY Readout Possible in 4Q20 BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is currently conducting the Phase 1b/2 TRANQUILITY clinical trial of BXCL501 for the acute treatment of agitation in patients with dementia, including Alzheimer’s disease (AD). The multicenter, randomized, double blind, placebo
- 08/17/2020
|
Why BioXcel Therapeutics Stock Is Down Today
- Shares of clinical-stage biotech BioXcel Therapeutics (NASDAQ: BTAI) are down by 9.9% as of 11:58 a.m. EDT on Friday, after the company released its second-quarter earnings report before the market opened.
- 08/14/2020
|
BioXcel Therapeutics' (BTAI) CEO Vimal Mehta on Q2 2020 Results - Earnings Call Transcript
- BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2020 Earnings Conference Call August 14, 2020 8:30 AM ET Company Participants Vimal Mehta – Chief Executive Officer Michael Stanton – Controller Rob Risinger – Senior Vice President-Clinical Development Will Kane – Chief Commercial Officer Reina Benabou – Chief Development Officer Conference Call Participants Geoff Meacham – Bank of America Robyn Karnauskas – Truist Securities Yatin Suneja – Guggenheim Partners Sumant Kulkarni – Canaccord Ram Selvaraju – H.C.
- 08/14/2020
|
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
- SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (“NDA”) submission to U.S. Food and Drug Administration (“FDA”) planned for Q1 2021 Initiating the third dose cohort, 90 mcg, of the TRANQUILITY trial in elderly dementia patientsInitiated a separate efficacy cohort in the Phase 2 trial of BXCL701 in combination with pembrolizumab (“KEYTRUDA®”) to include patients with castrate-resistant prostate cancer (“CRPC”)Strengthened balance sheet through follow-on offering raising approximately $200 million in gross proceedsCompany to host conference call today at 8:30 a.m. ETNEW HAVEN, Conn., Aug. 14, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced its quarterly results for the second quarter ended June 30, 2020 and provided an update on key strategic and operational initiatives.“Since inception, this is one of the most exciting times in the Company’s history,” stated Vimal Mehta, Chief Executive Officer of BTI. “First and foremost, we reported positive results from our two pivotal SERENITY trials last month that showed a robust treatment effect in reducing acute agitation in schizophrenia and bipolar disorder patients. We look forward to submitting an NDA for BXCL501 to the FDA in the first quarter of 2021 and, in preparation for a potential approval, we have made two key hires to lead commercialization and medical affairs. At the same time, we are advancing the TRANQUILITY and RELEASE trials in dementia and opioid withdrawal patients, respectively, and plan to initiate a trial in agitation associated with delirium patients this year, highlighting this candidate’s expected versatility across a wide range of diagnoses. We also continue to explore alternative indications associated with agitation, including alcohol withdrawal, post-traumatic stress disorder, traumatic brain injury and phobias. Finally, the successful completion of our recent follow-on equity offering puts us in a strong cash position to support BXCL501’s commercial launch, if approved, and our aggressive indication expansion strategy.”Dr. Mehta continued, “In addition, our immuno-oncology program is advancing. The Phase 2 efficacy trial of BXCL701 and KEYTRUDA® for treatment emergent Neuroendocrine Prostate Cancer continues to progress on track, and we have expanded this study to include a separate cohort of men with CRPC. Our MD Anderson-led Phase 2 basket trial in advanced solid tumors is also making great strides, now having met the efficacy bar in both arms necessary for the study to proceed to completion. We believe BXCL701 has the potential to bridge innate and adaptive immunity, as demonstrated by the increase in IL-18 from baseline, and we look forward to reporting initial efficacy data from both trials later this year.”Second Quarter 2020 and Recent HighlightsBXCL501-Neuroscience ProgramBXCL501 is an investigational sublingual thin film of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, designed for the treatment of acute agitation. The Company believes BXCL501 may directly target a causal agitation mechanism. * In July 2020, BTI reported that the pivotal Phase 3 SERENITY trials for the acute treatment of agitation in patients with schizophrenia and bipolar disorder met the primary, key secondary and exploratory endpoints. BXCL501 was well tolerated, with rapid and durable reductions in agitation. The Company has a pre-NDA meeting with the FDA this October and plans to submit an NDA for both indications in the first quarter of 2021. * The Company is initiating a third dose cohort, 90 mcg, in the TRANQUILITY study, a Phase 1b/2 trial of BXCL501 for the acute treatment of agitation associated with dementia. The adaptive trial is designed to identify the most effective and tolerable dose in this elderly patient population. BTI has successfully completed two lower-dose cohorts (30 mcg and 60 mcg) in a total of 30 patients. Based on findings from the 90 mcg cohort, the Company expects to report topline results in the fourth quarter of 2020, or, if needed, proceed to an additional dose cohort. * In June 2020, the first patient was enrolled in the RELEASE study, a Phase 1b/2 trial of BXCL501 for the acute treatment of opioid withdrawal symptoms, with the third cohort currently enrolling (90 mcg twice a day, 12 hours apart). The Company expects to report topline results from the study in the first quarter of 2021. * The Company expects to initiate a Phase 2 trial of BXCL501 in patients with agitation associated with delirium later this year. The planned study population will include ICU patients with or without COVID-19. This potential indication may offer synergy with the commercial infrastructure being developed to support our first NDA. * The Company received a Notice of Allowance from the U.S. Patent and Trademark office for patient application No. 16/453,679 related to BXCL501. The patent is expected to cover film formulations containing Dex and methods of treating agitation using such film formulations. The patent, which is anticipated to be issued in the third quarter of 2020, is expected to extend IP protection until 2039.BXCL701-Immuno-Oncology ProgramBXCL701 is an orally-delivered small molecule, innate immunity activator designed to inhibit dipeptidyl peptidase (DPP) 8/9 and block immune evasion by targeting Fibroblast Activation Protein (FAP). It has shown single agent activity in melanoma and safety has been evaluated in more than 700 healthy subjects and cancer patients. * The Phase 2 portion of the Phase 1b/2 trial of BXCL701 in combination with pembrolizumab (KEYTRUDA®) for treatment emergent Neuroendocrine Prostate Cancer (tNEPC) is advancing on track. Recently, BTI expanded the trial to include a separate cohort for CRPC (adenocarcinoma) patients who have failed taxane-based chemotherapy and up to two lines of second generation androgen pathway blockers, based on preliminary evidence of activity in this patient population in the safety cohort. The CRPC cohort is expected to run concurrently with the tNEPC cohort. Initial efficacy data from this trial are expected to be reported later this year. * The open label Phase 2 basket trial evaluating the combination of BXCL701 and KEYTRUDA® in patients with advanced solid cancers is proceeding, with early signs of clinical activity in several difficult-to-treat cancers. This study, which is being conducted at the MD Anderson Cancer Center, consists of two arms: checkpoint naïve patients and patients who are refractory to checkpoint therapy. In June, the safety portion of the trial was completed and in August, the efficacy bar was met for both arms of the trial, allowing the study to proceed to completion. Initial efficacy data are expected to be presented at a scientific conference later this year. * The BXCL701 phase of the triple combination study of BXCL701, bempegaldesleukin (NKTR-214, Nektar Therapeutics, Inc.) and BAVENCIO® (avelumab, Merck KGaA, Darmstadt, Germany and Pfizer) in second line pancreatic cancer is expected to begin following Nektar and Pfizer’s Phase 1b safety trial of a double combination of bempegaldesleukin and avelumab, pending the outcome of that trial. Corporate Highlights * In July 2020, the Company raised gross proceeds of approximately $200 million in connection with its common stock offering. BTI believes that the proceeds from this offering, together with current reserves, provide cash runway well into 2022 to fund key clinical, regulatory, operational, and commercial activities. * In June 2020, William Kane was appointed as Executive Vice President and Chief Commercial Officer of BTI. Mr. Kane brings over three decades of product commercialization experience in the pharmaceutical industry, with a proven track record in bringing neuropsychiatric drugs to market. * In June 2020, Reina Benabou, M.D., Ph.D. was appointed as Senior Vice President and Chief Development Officer of BTI. Dr. Benabou has over 20 years of experience in directing drug development programs and implementing medical affairs strategies for product commercialization in neurology and psychiatry.COVID-19During the second quarter of 2020, the Company remained committed to ensuring the health and safety of its patients, investigators and employees. BTI continued to assess the impact of the COVID-19 pandemic to best mitigate risk, while continuing business operations. Beginning at the end of the second quarter, BTI began to slowly bring a limited number of staff back to the Company’s office. This return to work is scheduled to be completed in September 2020. To date, the Company’s business and operations has only been minimally impacted and have not experienced any significant delays to our ongoing or planned clinical trials, except for challenges in accessing elderly care facilities; however, this could rapidly change.Second Quarter 2020 Financial ResultsBTI reported a net loss of $21.4 million for the second quarter of 2020, compared to a net loss of $8.5 million for the same period in 2019. The second quarter 2020 results include approximately $2.0 million in non-cash stock-based compensation, compared to $1.0 million for the same period in 2019.Research and development expenses were $17.9 million for the second quarter of 2020, compared to $6.5 million for the same period in 2019. The increase was primarily due to increases in clinical trial activity.General and administrative expenses were $3.5 million for the second quarter of 2020, as compared to $2.1 million for the same period in 2019. The increase was primarily due to salaries, non-cash compensation costs and professional fees.
- 08/14/2020
|
BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and Webcast
- NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Friday, August 14, 2020 at 8:30 AM Eastern Time to discuss its second quarter 2020 operating and financial results. Conference Call & Webcast DetailsDate/Time: Friday, August 14, 2020, 8:30 AM Eastern Time Domestic: 877-407-2985 International: 201-378-4915 The webcast will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.ReplayDomestic: 877-660-6853 International: 201-612-7415 Conference ID: 13708104 *Replay available through at least August 28, 2020About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.Contact Information:BioXcel Therapeutics, Inc. www.bioxceltherapeutics.comInvestor Relations:John Graziano jgraziano@troutgroup.com 1.646.378.2942Media:Julia Deutsch jdeutsch@troutgroup.com 1.646.378.2967
- 08/07/2020
|
BioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth Conference
- NEW HAVEN, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a virtual fireside chat at the Canaccord Genuity 40th Annual Growth Conference. Presentation Details:Event: Canaccord Genuity 40th Annual Growth ConferenceDate: Thursday, August 13, 2020Time: 1:00 PM ETA live webcast of the fireside chat will be accessible through the Investors section of the Company's website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the Company’s website for at least 30 days.About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.Contact Information:BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com Investor Relations: John Grazianojgraziano@troutgroup.com 1.646.378.2942 Media:Julia Deutschjdeutsch@troutgroup.com 1.646.378.2967
- 08/06/2020
|
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
- NEW HAVEN, Conn., July 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 4,000,000 shares of common stock at a public offering price of $50.00 per share. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds to BTI from the offering are expected to be $200 million, before deducting underwriting discounts and commissions and offering expenses. The Company will not receive any of the proceeds from any sale of shares in this offering by the selling stockholders. BofA Securities, Goldman Sachs & Co. LLC, Jefferies, Guggenheim Securities and SunTrust Robinson Humphrey are acting as book-running managers for the offering. The offering is expected to close on or about July 31, 2020, subject to customary closing conditions.The common stock is being offered by BTI pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) on July 27, 2020 and automatically became effective upon filing. This offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@bofa.com; Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Attn: Prospectus Department, Telephone 866-471-2526, Facsimile: 212-902-9316, Email: prospectus-ny@ny.email.gs.com; Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-821-7388, or by email at Prospectus_Department@Jefferies.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at 212-518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or SunTrust Robinson Humphrey, Inc., 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attn: Prospectus Department, Email: strh.prospectus@suntrust.com.This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.Forward-Looking Statement This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “being,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release.Contact Information Investor Relations: John Graziano jgraziano@troutgroup.com 1.646.378.2942Media: Julia Deutsch jdeutsch@troutgroup.com 1.646.378.2967
- 07/29/2020
|
The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
- 07/28/2020
|
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
- NEW HAVEN, Conn., July 27, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. In addition, certain selling stockholders expect to grant the underwriters a 30-day option to purchase up to $30.0 million of additional shares of common stock at the public offering price, less underwriting discounts and commissions. BofA Securities, Goldman Sachs & Co. LLC, Jefferies, Guggenheim Securities and SunTrust Robinson Humphrey are acting as book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.The Company intends to use the net proceeds of this offering to fund ongoing clinical trials, commercialization preparation and for general corporate purposes.The common stock is being offered by BTI pursuant to an automatic shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) on July 27, 2020 and automatically became effective upon filing. This offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@bofa.com; Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Attn: Prospectus Department, Telephone 866-471-2526, Facsimile: 212-902-9316, Email: prospectus-ny@ny.email.gs.com; Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-821-7388, or by email at Prospectus_Department@Jefferies.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at 212-518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or SunTrust Robinson Humphrey, Inc., 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attn: Prospectus Department, Email: strh.prospectus@suntrust.com.This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.Forward-Looking Statement This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “being,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release.Contact Information Investor Relations: John Graziano jgraziano@troutgroup.com 1.646.378.2942Media: Julia Deutsch jdeutsch@troutgroup.com 1.646.378.2967
- 07/27/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
BTAI: Positive Results in SERENITY Trials Puts NDA Filing on Track for 1Q21…
- By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Positive Results in Phase 3 SERENITY Trials On July 20, 2020, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced positive results from the SERENITY ( S ub-Lingual D E xmedetomidine in Agitation Associated With Schizoph RENI a and Bipolar Disorder S T ud Y ) trials of BXCL501 for treating agitation in patients with schizophrenia
- 07/22/2020
|
Bioxcel Therapeutics Hits Record On Bullish Test Results In Schizophrenia
- Bioxcel Therapeutics unveiled bullish Phase 3 results for an agitation treatment in patients with schizophrenia and bipolar disorder Monday — pushing BTAI stock to a record high.
- 07/20/2020
|
5 Stock Gainers for Monday: Daqo New Energy, BioXcel, Livongo
- Stocks rising Monday include Daqo New Energy, BioXcel Therapeutics, Peloton, Nantkwest and Altimmune.
- 07/20/2020
|
Why BioXcel Therapeutics Is Soaring Today
- BioXcel Therapeutics (NASDAQ: BTAI) is starting the week on a strong note. As of 11:31 a.m. EDT on Monday, shares of the biotech company are up by 14.4%. First, BioXcel reported positive results from two clinical trials for one of its lead pipeline candidates.
- 07/20/2020
|
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
- Highly statistically significant improvements in PEC score observed vs. placebo (p<0.0001) at two hours in the SERENITY trials for both doses tested Statistically.
- 07/20/2020
|
Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020
- Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneer
- 07/17/2020
|
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation
- NEW HAVEN, Conn., July 09, 2020 -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
- 07/09/2020
|
BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation
- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for patent application No. 16/453,679 related to BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine (“Dex”). The patent is expected to cover film formulations containing Dex and methods of treating agitation using such film formulations.
- 07/07/2020
|
Hedge Funds Are Warming Up To BioXcel Therapeutics, Inc. (BTAI)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 07/06/2020
|
Xconomy: Bio Roundup: Gilead's Pionyr Grab, Relay to IPO, Unicorn Sana & More
- Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside
- 06/26/2020
|
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 24)
ACADIA...
- 06/25/2020
|
The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
- 06/24/2020
|
BioXcel Therapeutics (BTAI) Investor Presentation - Slideshow
- The following slide deck was published by BioXcel Therapeutics, Inc. in conjunction with this event.
- 06/23/2020
|
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development Officer
- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced the appointment of Reina Benabou, M.D., Ph.D., as Senior Vice President and Chief Development Officer (CDO). Dr. Benabou has over 20 years of experience in directing drug development programs and implementing medical affairs strategies for product commercialization in neurology and psychiatry.
- 06/23/2020
|
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics
- 06/23/2020
|
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 18)
ADC Therapeutics SA (NYSE:...
- 06/19/2020
|
2 Stocks I’d Avoid at All Costs | The Motley Fool
- Here's why investors shouldn't bet on these two companies long-term, at least not yet.
- 06/18/2020
|
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
- 06/18/2020
|
3 “Strong Buy” Pharmaceutical Stocks With Major Catalysts Approaching
- Even during economic downturns, one fact remains resolute: pharma stocks represent the ultimate risk/reward plays. Out on Wall Street, the sector has become known for its high volatility. How did it earn this reputation? It comes down to the nature of the industry itself.Unlike companies in other areas of the market, pharma stocks depend less on earnings results, and more on clinical data and regulatory decisions. As the latter determine the trajectory of these stocks, a single piece of good news can act as a catalyst that sends shares skyrocketing.That being said, shares can plummet just as easily should a company publish lackluster data or if approvals don’t come through. For this reason, in-depth due diligence is necessary before pulling the trigger on a name in this sector.Today, we’ll look at three pharma stocks recommended by Sumant Kulkarni, a top-rated analyst from Canaccord. Kulkarni believes these three tickers could be propelled higher by upcoming clinical trial results that could be huge catalysts for each one. Indeed, according to TipRanks’ database, each ticker scores a “Strong Buy” consensus rating from the rest of the Street and boasts substantial upside potential.Zynerba Pharmaceuticals (ZYNE)Focused on developing transdermally-delivered cannabinoid therapeutics, Zynerba Pharmaceuticals wants to improve the lives of patients suffering from neuropsychiatric conditions like Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). On the heels of its recent positive data readout and more potential catalysts ahead, Kulkarni believes ZYNE's $5.50 share price looks like a steal.On May 27, ZYNE released data from its Phase 2 open-label BRIGHT trial studying Zygel (ZYN002), a transdermal synthetic cannabidiol gel, in ASD. Even though it’s still early, the data indicated that the asset could serve as an add-on treatment to the standard of care for the behavioral symptoms associated with the condition.Expounding on this, Kulkarni noted, “Specifically, Zygel ‘hit’ on all five sub-scales of the Aberrant Behavior Checklist - Community (ABC-C), and also on the Parent-Rated Anxiety Scale - ASD (PRAS-ASD), while retaining the relatively-benign safety/tolerability profile seen so far.” While certainly promising, focus remains primarily on the data readout for the double-blind, placebo-controlled, CONNECT-FX pivotal trial evaluating Zygel in FXS, which is slated for later this month. “Our view is there is limited read-through from today's ASD data to FXS, but we are encouraged Zygel appears to have activity on scales associated with social parameters. Our stock thesis is unchanged in that FXS has no approved products and trial data remain difficult to call, but we believe ZYNE presents significant opportunity for risk-tolerant investors going into the FXS data set,” Kulkarni commented. If that wasn’t enough, Kulkarni points to several other possible catalysts on the horizon. The verdict from ZYNE’s discussions with the FDA regarding Zygel’s DEE pivotal program is set to come in the next few weeks, with top-line results from the Phase 2 open-label INSPIRE study for Zygel in 22q coming the following quarter.To this end, Kulkarni rates ZYNE a Buy along with an $18 price target. This target implies shares could more than double in the next year. (To watch Kulkarni’s track record, click here) Like Kulkarni, other analysts also take a bullish approach. ZYNE’s Strong Buy consensus rating breaks down into 6 Buys and zero Holds or Sells. Given the $19.17 average price target, the upside potential lands at 249%. (See Zynerba stock analysis on TipRanks)BioXcel Therapeutics (BTAI)Next up we have BioXcel Therapeutics, which uses artificial intelligence (AI) to develop cutting-edge medicines across neuroscience and immuno-oncology. With two major potential catalysts in the near-term, it’s no wonder Wall Street focus has locked in on this name.On June 11, the company revealed that the first patient had been enrolled in RELEASE, its Phase 1b/2 trial assessing the use of BXCL501, a sublingual dexmedetomidine film, in treating opioid withdrawal symptoms.Weighing in on the implications of this development, Kulkarni said, “This on-time start means BXCL501 will move into a sub-chronic dosing setting vs. acute/rescue therapy for agitation where it is farther along in development. This move also ties into BTAI's strategy to build a broader/leading franchise around agitation, which is an approach that we continue to view as smart. We also remain impressed by management's ability to hit stated timelines, and look forward to RELEASE top-line data in 1Q21.”Speaking to the opportunity in this indication, there’s already a significant unmet need, and COVID-19 could potentially make the situation worse for many patients. As a result, Kulkarni projects a 2023 launch and unadjusted peak sales of $472 million in 2030.However, before this, data on the candidate’s use in treating agitation caused by other conditions is expected. Kulkarni is looking forward to the data readout for the Phase 3 SERENITY trial of BXCL501 in agitation in schizophrenia and bipolar disorder this July as well as the results from the Phase 1b/2 TRANQUILITY trial in dementia-induced agitation in mid-2020.Calling the above readouts “two key catalysts”, Kulkarni noted, “We continue to believe SERENITY data will come before TRANQUILITY, and like the risk-reward for the stock going into these events based on solid Phase 1b/2 data in schizophrenia, and proof-of-concept data in dementia.” The analyst added, “We model a probability of approval estimate of 75% for agitation in schizophrenia/bipolar disorder and our 2030E peak unadjusted sales are $313 million. We model 65% probability of approval in agitation in dementia, and our 2030E unadjusted peak sales are $584 million.”All of the above combined with other possible catalysts involving BXCL501 and BTAI’s other candidate, BXCL701, slated for 2H20 prompted Kulkarni to keep a Buy recommendation and $71 price target on the stock. Should the target be met, a twelve-month gain of 34% could be in store.All in all, other analysts are on the same page. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $89 average price target, which is more aggressive than Kulkarni’s, the upside potential comes in at 68%. (See BioXcel stock analysis on TipRanks)Intra-Cellular Therapies (ITCI)Founded on Nobel-prize winning research that uncovered how therapies impact the inner-workings of cells in the body, Intra-Cellular Therapies hopes to address the unmet needs of patients battling complex psychiatric and neurologic diseases. Ahead of an important possible catalyst, Kulkarni thinks ITCI is “significantly undervalued”.It should be noted that its most recent quarter saw the company achieve a major milestone as its recently-approved Caplyta product, lumateperone, for schizophrenia, was launched. Only on the market since March 23, the asset generated just under $1 million in sales, with Kulkarni calling for $1.1 million. This is impressive as the estimate wasn’t updated after the onset of the COVID-19 pandemic.“Given the current environment, we get the sense that ITCI has been nimble enough to adapt well and has also made good progress with payers... We continue to believe Caplyta could generate meaningful sales in schizophrenia, and at these levels we are BUYERS on this opportunity alone.” Kulkarni explained.Also noteworthy for Kulkarni, though, is the publication of data from the Phase 3 global adjunct trial for lumateperone in bipolar depression, which is set to come in mid-20. Additionally, the analyst points out that ITCI should provide updates regarding its discussions with the FDA on this indication.“That said, we also like the stock going into the mid-20 Phase 3 data for lumateperone in bipolar depression, which represents greater unmet need and is a potentially larger market opportunity with fewer approved products,” Kulkarni stated. The analyst added, “Recall that in 1Q20, ITCI started another monotherapy Phase 3 trial (global) with results expected in 2H21. ITCI, however, expects to send in a supplemental new drug application (sNDA) for bipolar depression in late-2020. With a successful global monotherapy trial and a U.S. trial with mixed results, we believe ITCI has a solid shot at a potential approval in this indication.”The good news didn’t end there. Kulkarni believes that the possible upside drivers extend beyond lumateperone, with Phase 1/2 data for ITI-214 in heart failure expected in the next few weeks.It should come as no surprise, then, that Kulkarni stayed with the bulls. In addition to keeping a Buy rating on the stock, the analyst maintained a $70 price target, which brings the upside potential to 215%.Do other analysts agree with Kulkarni? As it turns out, they do. Only Buy ratings, 3 to be exact, have been received in the last three months, so the consensus rating is a Strong Buy. At $47.67, the average price target indicates 115% upside potential. (See Intra-Cellular stock-price forecast on TipRanks)To find good ideas for pharma stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 06/17/2020
|
BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer
- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced the appointment of Will Kane as Executive Vice President and Chief Commercial Officer (CCO). Mr. Kane brings over three decades of product commercialization experience in the pharmaceutical industry, most recently as the Head of the U.S. General Medicine business unit at Allergan.
- 06/16/2020
|
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 16)
Applied Molecular Transport...
- 06/16/2020
|
BioXcel Therapeutics to Participate in Two Upcoming Investor Conferences
- NEW HAVEN, Conn., June 15, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.
- 06/15/2020
|
Analysts Offer Insights on Healthcare Companies: CytoDyn (Other OTC: CYDY), Bioxcel Therapeutics (NASDAQ: BTAI) and SLANG Worldwide (Other OTC: SLGWF) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CytoDyn (CYDY
- 06/12/2020
|
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that the first patient has been enrolled in the Phase 1b/2 RELEASE trial of BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine (“Dex”), for the treatment of opioid withdrawal symptoms. “The initiation of the RELEASE trial is a major milestone for our neuroscience program, as we believe it not only showcases BXCL501’s promise across multiple indications, but also supports this candidate’s potential as a sub-chronic treatment,” commented Vimal Mehta, Ph.D., Chief Executive Officer of BTI.
- 06/11/2020
|
The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 4)
Biohaven Pharmaceutical...
- 06/05/2020
|
Benzinga's Top Upgrades, Downgrades For June 4, 2020
- Upgrades * For American Eagle Outfitters Inc (NYSE: AEO), Morgan Stanley upgraded the stock from Underweight to Equal-Weight. For the first quarter, American Eagle Outfitters had an EPS of ($0.84), compared to year-ago quarter EPS of $0.24. The stock has a 52-week-high of $19.90 and a 52-week-low of $6.54. American Eagle Outfitters's stock last closed at $11.81 per share. * For Comerica Inc (NYSE: CMA), B. Riley FBR upgraded the stock from Neutral to Buy. In the first quarter, Comerica showed an EPS of ($0.46), compared to $2.08 from the year-ago quarter. The stock has a 52-week-high of $74.11 and a 52-week-low of $24.28. Comerica's stock last closed at $40.04 per share. * Oppenheimer upgraded the stock for Sally Beauty Holdings Inc (NYSE: SBH) from Perform to Outperform. Sally Beauty Holdings earned $0.23 in the second quarter, compared to $0.51 in the year-ago quarter. The stock has a 52-week-high of $21.98 and a 52-week-low of $6.28. Sally Beauty Holdings's stock last closed at $15.21 per share. * Citigroup changed the rating for SeaWorld Entertainment Inc (NYSE: SEAS) from Neutral to Buy. In the first quarter, SeaWorld Entertainment showed an EPS of ($0.72), compared to ($0.41) from the year-ago quarter. The stock has a 52-week-high of $36.96 and a 52-week-low of $6.75. SeaWorld Entertainment's stock last closed at $18.57 per share. * Baird changed the rating for Sykes Enterprises Inc (NASDAQ: SYKE) from Neutral to Outperform. Sykes Enterprises earned $0.44 in the first quarter, compared to $0.45 in the year-ago quarter. The stock has a 52-week-high of $38.24 and a 52-week-low of $22.12. Sykes Enterprises's stock last closed at $28.58 per share. * For Targa Resources Corp (NYSE: TRGP), Barclays upgraded the stock from Equal-Weight to Overweight. In the first quarter, Targa Resources showed an EPS of $0.00, compared to ($0.30) from the year-ago quarter. The stock has a 52-week-high of $43.47 and a 52-week-low of $3.66. Targa Resources's stock last closed at $20.47 per share. * Bernstein upgraded the stock for Tyson Foods Inc (NYSE: TSN) from Market Perform to Outperform. In the second quarter, Tyson Foods showed an EPS of $0.77, compared to $1.20 from the year-ago quarter. The stock has a 52-week-high of $94.24 and a 52-week-low of $42.57. Tyson Foods's stock last closed at $60.09 per share. * Deutsche Bank upgraded the stock for Wells Fargo & Co (NYSE: WFC) from Hold to Buy. Wells Fargo earned $0.80 in the first quarter, compared to $1.20 in the year-ago quarter. The stock has a 52-week-high of $54.75 and a 52-week-low of $22.00. Wells Fargo's stock last closed at $28.81 per share. * For Methanex Corp (NASDAQ: MEOH), ScotiaBank upgraded the stock from Sector Perform to Sector Outperform. In the first quarter, Methanex showed an EPS of $0.10, compared to $0.73 from the year-ago quarter. The stock has a 52-week-high of $47.55 and a 52-week-low of $9.00. Methanex's stock last closed at $19.42 per share. * For Evergy Inc (NYSE: EVRG), Evercore ISI Group upgraded the stock from In-Line to Outperform. Evergy earned $0.41 in the first quarter, compared to $0.44 in the year-ago quarter. The stock has a 52-week-high of $76.57 and a 52-week-low of $42.01. Evergy's stock last closed at $63.44 per share. Downgrades * Pareto changed the rating for International Seaways Inc (NYSE: INSW) from Buy to Hold. For the first quarter, International Seaways had an EPS of $1.49, compared to year-ago quarter EPS of $0.37. The stock has a 52-week-high of $31.39 and a 52-week-low of $14.89. International Seaways's stock last closed at $20.74 per share. * Citigroup changed the rating for Qudian Inc (NYSE: QD) from Neutral to Sell. Qudian earned ($0.50) in the first quarter, compared to $0.49 in the year-ago quarter. The stock has a 52-week-high of $9.21 and a 52-week-low of $1.21. Qudian's stock last closed at $1.54 per share. * Pareto changed the rating for Scorpio Tankers Inc (NYSE: STNG) from Buy to Hold. For the first quarter, Scorpio Tankers had an EPS of $0.82, compared to year-ago quarter EPS of $0.30. The stock has a 52-week-high of $40.45 and a 52-week-low of $12.35. Scorpio Tankers's stock last closed at $16.91 per share. * For Goldman Sachs Group Inc (NYSE: GS), Deutsche Bank downgraded the stock from Buy to Hold. Goldman Sachs Group earned $3.11 in the first quarter, compared to $5.71 in the year-ago quarter. The stock has a 52-week-high of $250.46 and a 52-week-low of $130.85. Goldman Sachs Group's stock last closed at $210.63 per share. * For Planet Fitness Inc (NYSE: PLNT), Raymond James downgraded the stock from Outperform to Market Perform. For the first quarter, Planet Fitness had an EPS of $0.16, compared to year-ago quarter EPS of $0.35. The stock has a 52-week-high of $88.77 and a 52-week-low of $23.77. Planet Fitness's stock last closed at $77.27 per share. Initiations * Guggenheim initiated coverage on BioXcel Therapeutics Inc (NASDAQ: BTAI) with a Buy rating. The price target for BioXcel Therapeutics is set at $101.00. BioXcel Therapeutics earned ($0.79) in the first quarter, compared to ($0.46) in the year-ago quarter. The stock has a 52-week-high of $51.83 and a 52-week-low of $3.76. BioXcel Therapeutics's stock last closed at $45.14 per share. * Roth Capital initiated coverage on Delcath Systems Inc (NASDAQ: DCTH) with a Buy rating. The price target for Delcath Systems is set at $20.00. In the first quarter, Delcath Systems showed an EPS of ($108.07), compared to ($0.11) from the year-ago quarter. The stock has a 52-week-high of $13.00 and a 52-week-low of $6.06. Delcath Systems's stock last closed at $7.75 per share. * With a rating of Neutral, Compass Point initiated coverage on Macerich Co (NYSE: MAC). The price target is set at $9.00 for Macerich. Macerich earned $0.81 in the first quarter, compared to $0.81 in the year-ago quarter. The stock has a 52-week-high of $37.82 and a 52-week-low of $4.81. Macerich's stock last closed at $8.58 per share. * With a rating of Overweight, Barclays initiated coverage on Plug Power Inc (NASDAQ: PLUG). The price target is set at $7.00 for Plug Power. In the first quarter, Plug Power showed an EPS of ($0.12), compared to ($0.15) from the year-ago quarter. The stock has a 52-week-high of $6.05 and a 52-week-low of $1.86. Plug Power's stock last closed at $4.17 per share. * With a rating of Outperform, RBC Capital initiated coverage on Provention Bio Inc (NASDAQ: PRVB). The price target is set at $25.00 for Provention Bio. For the first quarter, Provention Bio had an EPS of $0.26, compared to year-ago quarter EPS of ($0.29). The stock has a 52-week-high of $22.82 and a 52-week-low of $4.00. Provention Bio's stock last closed at $14.48 per share. * With a rating of Sell, Compass Point initiated coverage on Tanger Factory Outlet Centers Inc (NYSE: SKT). The price target is set at $6.00 for Tanger Factory Outlet. For the first quarter, Tanger Factory Outlet had an EPS of $0.50, compared to year-ago quarter EPS of $0.57. The stock has a 52-week-high of $17.94 and a 52-week-low of $4.05. Tanger Factory Outlet's stock last closed at $7.41 per share. * With a rating of Neutral, Compass Point initiated coverage on Taubman Centers Inc (NYSE: TCO). The price target is set at $42.00 for Taubman Centers. In the first quarter, Taubman Centers showed an EPS of $0.88, compared to $0.95 from the year-ago quarter. The stock has a 52-week-high of $53.40 and a 52-week-low of $26.24. Taubman Centers's stock last closed at $42.42 per share. * KeyBanc initiated coverage on PPD Inc (NASDAQ: PPD) with an Overweight rating. The price target for PPD is set at $35.00. In the first quarter, PPD earned $0.24. The stock has a 52-week-high of $33.23 and a 52-week-low of $10.61. PPD's stock last closed at $28.59 per share. * H.C. Wainwright initiated coverage on Actinium Pharmaceuticals Inc (AMEX: ATNM) with a Buy rating. The price target for Actinium Pharmaceuticals is set at $3.00. For the fourth quarter, Actinium Pharmaceuticals had an EPS of ($0.03), compared to year-ago quarter EPS of ($0.05). The stock has a 52-week-high of $0.41 and a 52-week-low of $0.16. Actinium Pharmaceuticals's stock last closed at $0.22 per share.See more from Benzinga * Duluth Holdings: Q1 Earnings Insights * Recap: Toro Q2 Earnings * Recap: Orion Energy Systems Q4 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/04/2020
|
BioXcel Therapeutics to Present at the Jefferies Virtual Healthcare Conference
- NEW HAVEN, Conn., May 28, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.
- 05/28/2020
|
The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 19)
ADC Therapeutics SA (NYSE:...
- 05/20/2020
|
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 18)
ADC Therapeutics SA (NYSE:...
- 05/19/2020
|
BTAI: Phase 3 Data from SERENITY Trials in July 2020…
- By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT BioXcel Therapeutics, Inc. (NASDAQ:BTAI) currently has two lead development programs: BXCL501 – a sublingual formulation of the α2a adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of neurological and psychiatric disorders; and BXCL701 – an immuno-oncology agent for treatment of a rare form of prostate cancer
- 05/15/2020
|
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 14)
Allogene Therapeutics Inc (...
- 05/15/2020
|
BioXcel Therapeutics Announces Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501
- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced full enrollment of its pivotal Phase 3 SERENITY trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder. The Company expects to report topline data from both trials in July of 2020.
- 05/14/2020
|
8-K: BioXcel Therapeutics, Inc.
- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
- 05/13/2020
|
BioXcel Therapeutics, Inc. (BTAI) Q1 2020 Earnings Call Transcript
- Good morning, everyone, and thank you for joining our conference call to discuss BioXcel Therapeutics' financial results and business highlights for the first-quarter 2020. Joining me for the call today are Richard Steinhart, chief financial officer; Frank Yocca, chief scientific officer; and Vince O'Neill, chief medical officer.
- 05/13/2020
|
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
- 05/13/2020
|
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2020 Results - Earnings Call Transcript
- BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2020 Results Conference Call May 12, 2020 08:30 AM ET Company Participants Vimal Mehta - Founder and CEO Richard Ste
- 05/12/2020
|
BioXcel Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
- Enrollment of the pivotal SERENITY trials is progressing well, with topline data expected in mid-2020 The Company is assessing data for dose escalation in the.
- 05/12/2020
|
The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Acceleron Pharma Inc (NASDAQ...
- 05/12/2020
|
BioXcel Therapeutics to Present at the UBS Virtual Global Healthcare Conference
- NEW HAVEN, Conn., May 11, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.
- 05/11/2020
|
Global Pancreatic Cancer Markets, Drugs and Companies 2016-2024 - ResearchAndMarkets.com
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
BioXcel Therapeutics to Present at the BofA Securities Virtual Health Care Conference
- NEW HAVEN, Conn., May 07, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.
- 05/07/2020
|
BioXcel Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast
- NEW HAVEN, Conn., May 05, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
- 05/05/2020
|
Canaccord Genuity Believes Bioxcel Therapeutics (BTAI) Won't Stop Here
- Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Bioxcel Therapeutics (BTAI) today and set a price target of $68.00. The company's
- 05/01/2020
|
Canaccord Genuity Believes Bioxcel Therapeutics (NASDAQ: BTAI) Won’t Stop Here
- Canaccord Genuity analyst
Sumant Kulkarni
maintained a
Buy
rating on Bioxcel Therapeutics (
BTAI
–
Research Report
) today and set a price target of
$68.00
. The company’s shares closed last Thursday at $37.00, close to its 52-week high of $43.63.
Ac
- 05/01/2020
|
H.C. Wainwright Keeps a Buy Rating on Bioxcel Therapeutics (BTAI)
- In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics (BTAI), with a price target of $95.00. The
- 04/28/2020
|
BioXcel Therapeutics Announces Initiation of a Phase 2 Study of BXCL701 in Combination with a PD-1 Inhibitor for Treatment Emergent Neuroendocrine Prostate Cancer
- BioXcel Therapeutics (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced the initiation of the Phase 2 efficacy portion of the Phase
- 04/28/2020
|
Artemis Investment Management LLP Has $17.38 Million Stake in BioXcel Therapeutics Inc (NASDAQ:BTAI)
- Artemis Investment Management LLP trimmed its position in BioXcel Therapeutics Inc (NASDAQ:BTAI) by 26.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 786,958 shares of the company’s stock after selling 286,633 shares during the quarter. Artemis Investment Management LLP […]
- 04/28/2020
|
BioXcel Therapeutics (NASDAQ:BTAI) Upgraded to "Strong-Buy" at BidaskClub
- BidaskClub upgraded shares of BioXcel Therapeutics (NASDAQ:BTAI) from a buy rating to a strong-buy rating in a research note published on Tuesday, BidAskClub reports. Several other research firms also recently issued reports on BTAI. Canaccord Genuity restated a buy rating on shares of BioXcel Therapeutics in a research report on Tuesday, March 10th. ValuEngine upgraded […]
- 04/25/2020
|
Head-To-Head Review: Crinetics Pharmaceuticals (NASDAQ:CRNX) and BioXcel Therapeutics (NASDAQ:BTAI)
- Crinetics Pharmaceuticals (NASDAQ:CRNX) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends. Profitability This table compares Crinetics Pharmaceuticals and BioXcel Therapeutics’ net margins, return on equity and […]
- 04/25/2020
|
How BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Can Impact Your Portfolio Volatility
- If you're interested in BioXcel Therapeutics, Inc. (NASDAQ:BTAI), then you might want to consider its beta (a measure...
- 04/24/2020
|
BioXcel Therapeutics CEO Says Wearable Devices Are Another Tool To Combat Alzheimer's Agitation
- BioXcel Therapeutics (NASDAQ: BTAI) founder and CEO Dr. Mehta Vimal spoke with Benzinga about its BXCL-501 drug candidate for agitation in Alzheimer's patients —...
- 04/15/2020
|
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals (MDGL) and CareDx (CDNA)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals
- 04/15/2020
|
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (NASDAQ: BTAI), Madrigal Pharmaceuticals (NASDAQ: MDGL) and CareDx (NASDAQ: CDNA)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics
- 04/15/2020
|
BioXcel Therapeutics Inc (NASDAQ:BTAI) Receives Average Recommendation of "Buy" from Brokerages
- Shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) have earned an average recommendation of “Buy” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among […]
- 04/10/2020
|
Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020
- NEW YORK, NY / ACCESSWIRE / April 6, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a fourth day of presentations as part ...
- 04/06/2020
|
Fly Intel: Top five analyst initiations ZM;BTAI;PROF;AEO;HBI;ESPR;KNSA
- Fly Intel: Top five analyst initiations ZM BTAI PROF AEO HBI ESPR KNSA
- 04/01/2020
|
Oppenheimer sees 26% downside in Intuitive Surgical in premarket action
- Apellis Pharmaceuticals (NASDAQ:APLS) initiated with Strong Buy rating and $86 (221% upside) price target at Raymond James.BioXcel Therapeutics (NASDAQ:BTAI) initiated with Buy rating and $45 (101% up
- 04/01/2020
|
Biotech stocks have held up better than the broader market — and these five are potential winners
- Landmine No. 1: Smaller biotech companies short on cash will face a funding crunch if the stock market stays down. How to diffuse it: Favor biotech companies that just raised cash, or have enough on hand to cover at least 18 months of cash burn, says Jefferies biotech analyst Michael Yee. Several companies were lucky enough to raise capital right before the biotech group started to fall apart on March 6.
- 03/24/2020
|
Bioxcel Therapeutics (BTAI) Received its Third Buy in a Row
- After Canaccord Genuity and BMO Capital gave Bioxcel Therapeutics (NASDAQ: BTAI) a Buy rating last month, the company received another Buy, this time from
- 03/19/2020
|
Bioxcel Therapeutics (BTAI) Received its Third Buy in a Row
- After Canaccord Genuity and BMO Capital gave Bioxcel Therapeutics (NASDAQ: BTAI) a Buy rating last month, the company received another
- 03/19/2020
|
BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials
- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that more than one-third of the patients in the Phase 3 SERENITY trials have been enrolled and treated. To date, the company has not observed a change in enrollment rates resulting from the COVID-19 pandemic, and currently maintains previous guidance that SERENITY I & II are expected to be completed by mid-year 2020.
- 03/19/2020
|
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and SI-Bone (SIBN)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioxcel Therapeutics (BTAI) and SI-Bone (SIBN) with bullish
- 03/10/2020
|
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (NASDAQ: BTAI) and SI-Bone (NASDAQ: SIBN)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioxcel Therapeutics (
BTAI
–
Research Report
) and SI-Bone (
SIBN
–
Research Report
) with bullish sentiments.
Bioxcel Therapeutics (BTAI)
Canaccord Genui
- 03/10/2020
|
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- Key BXCL501 data readouts expected in mid-2020 – including results from the SERENITY program and the Phase 1b/2 TRANQUILITY trial in geriatric dementia Strengthened balance.
- 03/09/2020
|
BioXcel Therapeutics, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 9, 2020 / BioXcel Therapeutics, Inc. (BTAI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 9, 2020 at 8:30 AM ...
- 03/09/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news. View more earnings on IBBThe following are key catalysts in the unfolding week that a biotech
- 03/08/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
Ignore the Coronavirus Panic and Stop Selling
- Unsurprisingly, the mainstream media has it all wrong. The coronavirus isn't the end of the world. Stop selling and start profiting now.
- 03/03/2020
|
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast
- NEW HAVEN, Conn., March 02, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
- 03/02/2020
|
BYND, ALC among premarket gainers
- SELLAS Life Sciences Group (NASDAQ:SLS) +23% on positive follow-up phase 1/2 clinical data for Galinpepimut-S in acute myeloid leukemia.Alcon (NYSE:ALC) +10% on Q4 results.Moderna (NASDAQ:MRNA) +9% on
- 02/26/2020
|
BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
- NEW HAVEN, Conn., Feb. 26, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
- 02/26/2020
|
3 Biotech Stocks That Surged Last Week
- See if they can keep climbing.
- 02/24/2020
|
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA)
- 02/21/2020
|
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (
BTAI
–
Research Report
), Atara Biotherapeutics (
ATRA
–
Research Report
) and Globus Medical (
GMED
–
Research Report
) with bullis
- 02/21/2020
|
VIAC, WIX among premarket losers
- Tivity Health (NASDAQ:TVTY) -39% on Q4 earnings.Six Flags Entertainment (NYSE:SIX) -18% on Q4 earnings.BioXcel Therapeutics (NASDAQ:BTAI) -17% after pricing equity offering.Axovant Gene Therapies (NAS
- 02/20/2020
|
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 2,000,000 shares of common stock at a public offering price of $32.00 per share. In addition, BTI has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock from BTI at the public offering price, less underwriting discounts and commissions. Gross proceeds to BTI from the offering are expected to be approximately $64.0 million, before deducting underwriting discounts and commissions and offering expenses.
- 02/20/2020
|
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ...
- 02/20/2020
|
3 Biotech Stocks That Already Doubled This Year
- Can these soaring biotech stocks keep climbing?
- 02/20/2020
|
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. In connection with the offering, BTI intends to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock from BTI. To the extent the underwriters exercise their option to purchase additional shares of common stock, the Company intends to use the net proceeds from the sale of additional shares to repurchase shares of common stock (which shares will then be canceled) from BioXcel Corporation at a price equal to the price paid by the underwriters for such shares in the public offering.
- 02/19/2020
|
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex ...
- 02/19/2020
|
76 Biggest Movers From Friday
- Gainers
Summer Infant, Inc. (NASDAQ: SUMR) shares climbed 288% to close at $1.05 on Friday after the company reported restructuring of its business, which is expected to result...
- 02/18/2020
|
Fly Intel: Wall Street's top stories at midday NVDA;EXPE;MAT;YELP;BTAI;IMGN;CGC;PINS;FB;CARG;LPSN
- Fly Intel: Wall Street's top stories at midday NVDA EXPE MAT YELP BTAI IMGN CGC PINS FB CARG LPSN
- 02/14/2020
|
50 Stocks Moving In Friday's Mid-Day Session
- Gainers
Genprex, Inc. (NASDAQ: GNPX) shares gained 90.5% to $5.22 after climbing 51.38% on Thursday.
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares jumped 49.7% to $35.71...
- 02/14/2020
|
Mid-Day Market Update: ImmunoGen Surges On Upbeat Q4 Results; LivePerson Shares Plummet
- Midway through trading Friday, the Dow traded down 0.09% to 29396.47 while the NASDAQ rose 0.21% to 9731.88. The S&P also rose, gaining 0.08% to 3,376.77.
Leading and Lagging...
- 02/14/2020
|
Mid-Morning Market Update: Markets Mostly Flat; NVIDIA Posts Upbeat Q4 Earnings
- Following the market opening Friday, the Dow traded down 0.07% to 29402.70 while the NASDAQ rose 0.05% to 9,716.50. The S&P also fell, dropping 0.01% to 3,373.51.
Leading and...
- 02/14/2020
|
NVDA, ACB among premarket gainers
- BioXcel Therapeutics (NASDAQ:BTAI) +67%.Canopy Growth (NYSE:CGC) +24% on Q3 results.Blink Charging (NASDAQ:BLNK) +25%.ImmunoGen (NASDAQ:IMGN) +16% on Q4 results.Genprex (NASDAQ:GNPX) +14%.Medigus (NAS
- 02/14/2020
|
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
- 02/14/2020
|
16 Healthcare Stocks Moving In Friday's Pre-Market Session
- Gainers
• Immunogen, Inc. (NASDAQ:IMGN) stock rose 21.1% to $6.49 during Friday's pre-market session.
• Canopy Growth, Inc. (NYSE:CGC) shares rose 20.4% to $23.51....
- 02/14/2020
|
9 Biotechnology Stocks Moving In Friday's Pre-Market Session
- Gainers
• Immunogen, Inc. (NASDAQ:IMGN) shares rose 21.1% to $6.49 during Friday's pre-market session.
• Inovio Pharmaceuticals, Inc. (NASDAQ:INO) stock rose 14.0%...
- 02/14/2020
|
77 Biggest Movers From Yesterday
- Gainers
Revolution Medicines, Inc. (NASDAQ: RVMD) shares surged 70% to close at $28.90 on Thursday. Revolution Medicines priced 14 million share IPO at $17 per share.
BioXcel...
- 02/14/2020
|
INO, CRSP among premarket gainers
- CounterPath (NASDAQ:CPAH) +49% on securing five-year deal with Vodafone Fiji to extend superior quality voice services to consumers.Alpha Pro Tech (NYSEMKT:APT) +29% as orders surge for Alpha Pro Tech
- 02/13/2020
|
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...
- 02/06/2020
|
BioXcel Therapeutics: AI-Focused Biopharmaceutical Player For 2020
- BXCL501 is a major driving force for BioXcel Therapeutics. The company is targeting a billion-dollar opportunity in agitation space. Investors should consider t
- 01/23/2020
|
JNUG, TVIX, VCYT, AAXN, IIN, WTW
- Stocks Analysis by Harry Boxer covering: Intuitive Surgical Inc, Axon Enterprise Inc, IntriCon Corporation, WW International Inc. Read Harry Boxer's latest article on Investing.com
- 01/04/2019
|
